Published in Cancer Weekly, November 17th, 2009
"We conducted a retrospective study involving 23 tertiary referral centers in 12 European, Asian, and Oceanian countries. One hundred DTC patients (69% female, 31% male, 84% papillary, 61% N1, 18% M1) ages 4.9-18 yr at first rhTSH administration were studied. A total of 181 rhTSH courses...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.